Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy

Table 3 Posterior probability of non-inferiority for FF/VI versus other relevant ICS/LABA combination therapies*

A
Treatment	Comparator	Mean difference, ml (95 % CrI)	Probability of non-inferiority Margin (ml)
Treatment	Comparator	Mean difference, ml (95 % CrI)	75	100	125
FF/VI 92/22	FP/SAL 250/50	−0.046 (−0.102–0.010)	84 %	97 %	>99 %
FF/VI 92/22	BUD/FORM 320/9	−0.037 (−0.106–0.032)	86 %	96 %	99 %
FF/VI 184/22	FP/SAL 500/50	0.163 (0.058–0.269)	>99 %	>99 %	>99 %
FF/VI 184/22	BUD/FORM 640/18	0.099 (−0.043–0.241)	99 %	>99 %	>99 %
B
Treatment	Comparator	Mean difference, units (95 % CrI)	Probability of non-inferiority Margin (units)
Treatment	Comparator	Mean difference, units (95 % CrI)	0.25		0.5
FF/VI 92/22	FP/SAL 250/50	93 (−43–230)	>99 %		>99 %
FF/VI 92/22	BUD/FORM 320/9	89 (−502–680)	93 %		95 %

For studies requiring patients to be treated with ICS only at baseline
*Other relevant ICS/LABA: FP/SAL 250/50 mcg and 500/50 mcg; BUD/FORM 320/9 mcg and 640/18 mcg
a) change from baseline in FEV₁. b) AQLQ Total score^#
Note: All stated doses are mcg
^# For reasons of model stability, only study length was included as a covariate in analysis of moderate/severe exacerbations data
AQLQ Asthma quality of life questionnaire, BUD Budesonide, CrI Credible interval, FORM Formoterol, FEV ₁ Forced expiratory volume in 1 s, FF Fluticasone furoate, FP Fluticasone propionate, SAL Salmeterol, VI Vilanterol

ISSN: 2054-7064